AUTHOR=Li Jinze , Cao Dehong , Huang Yin , Xiong Qiao , Tan Daqing , Liu Liangren , Lin Tianhai , Wei Qiang 

TITLE=The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer

JOURNAL=Frontiers in Immunology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.865643

DOI=10.3389/fimmu.2022.865643

ISSN=1664-3224

ABSTRACT=Background: Systemic immune-inflammation index (SII) has recently emerged as a biomarker for the prognosis of a variety of malignant tumors. However, the role of SII in bladder cancer (BC) remains unclear. To this end, we performed a pooled analysis to investigate the prognostic value of preoperative SII in patients with BC.
Methods: A comprehensive search of electronic databases (PubMed/Medline, Web of Science, Scopus, and Cochrane Central) was conducted to determine the eligible studies that were published until January 2022. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the association between preoperative SII and the prognosis, clinicopathological characteristics of BC.
Results: Ten studies with 7087 patients were included in this analysis. SII was observed to be correlated with inferior overall survival (HR = 1.41, 95% CI 0.98-2.02, p = 0.066), cancer-specific survival (HR = 1.68, 95% CI 1.14-2.47, p = 0.009), and recurrence-free survival (HR = 1.29, 95% CI 1.03-1.61, p = 0.027). An increased preoperative SII was also associated with poor tumor differentiation, higher tumor stage, presence of lymph node involvement, and tumor size ≥3cm (all p < 0.05).
Conclusions: An elevated preoperative SII is significantly associated with worse survival outcomes and adverse pathological features in patients with BC. Hence, SII may serve as a strong independent prognostic predictor for patients with BC after surgery.